Views of Wall Street’s Leading Experts on Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc. (NASDAQ: COLL) stock jumped 1.24% on Tuesday to $28.58 against a previous-day closing price of $28.23. With 0.57 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.31 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $29.00 whereas the lowest price it dropped to was $27.43. The 52-week range on COLL shows that it touched its highest point at $29.78 and its lowest point at $14.04 during that stretch. It currently has a 1-year price target of $36.00. Beta for the stock currently stands at 0.76.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of COLL was up-trending over the past week, with a rise of 0.67%, but this was up by 24.26% over a month. Three-month performance surged to 63.03% while six-month performance rose 63.22%. The stock gained 61.38% in the past year, while it has gained 23.19% so far this year. A look at the trailing 12-month EPS for COLL yields -1.26 with Next year EPS estimates of 1.93. For the next quarter, that number is -0.19. This implies an EPS growth rate of 143.90% for this year and 379.70% for next year. EPS is expected to grow by 0.55% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 19.90%.

Float and Shares Shorts:

At present, 34.57 million COLL shares are outstanding with a float of 33.15 million shares on hand for trading. On Oct 13, 2022, short shares totaled 3.9 million, which was 11.42% higher than short shares on Sep 14, 2022. In addition to Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph. as the firm’s Co-Founder & Chairman, Mr. Joseph J. Ciaffoni serves as its Pres, CEO & Director.

Institutional Ownership:

Through their ownership of 110.74% of COLL’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 58.17% of COLL, in contrast to 50.33% held by mutual funds. Shares owned by individuals account for 20.82%. As the largest shareholder in COLL with 15.58% of the stake, BlackRock Fund Advisors holds 5,231,124 shares worth 5,231,124. A second-largest stockholder of COLL, Rubric Capital Management LP, holds 3,333,628 shares, controlling over 9.93% of the firm’s shares. Eventide Asset Management LLC is the third largest shareholder in COLL, holding 2,629,593 shares or 7.83% stake. With a 7.40% stake in COLL, the iShares Core S&P Small Cap ETF is the largest stakeholder. A total of 2,483,546 shares are owned by the mutual fund manager. The Catalyst Eventide Gilead Fund, which owns about 4.00% of COLL stock, is the second-largest Mutual Fund holder. It holds 1,344,376 shares valued at 31.19 million. Eventide Healthcare & Life Scienc holds 3.83% of the stake in COLL, owning 1,285,217 shares worth 29.82 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for COLL since 6 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With COLL analysts setting a high price target of $40.00 and a low target of $33.00, the average target price over the next 12 months is $35.75. Based on these targets, COLL could surge 39.96% to reach the target high and rise by 15.47% to reach the target low. Reaching the average price target will result in a growth of 25.09% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. COLL will report FY 2022 earnings on 02/23/2024. Analysts have provided yearly estimates in a range of $4.68 being high and $3.77 being low. For COLL, this leads to a yearly average estimate of $4.27. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Collegium Pharmaceutical Inc. surprised analysts by -$0.28 when it reported $1.10 EPS against a consensus estimate of $1.38. The surprise factor in the prior quarter was -$0.26. Based on analyst estimates, the high estimate for the next quarter is $1.98 and the low estimate is $0.88. The average estimate for the next quarter is thus $1.17.

Summary of Insider Activity:

Insiders traded COLL stock several times over the past three months with 17 Buys and 24 Sells. In these transactions, 377,362 shares were bought while 469,899 shares were sold. The number of buy transactions has increased to 38 while that of sell transactions has risen to 45 over the past year. The total number of shares bought during that period was 984,167 while 691,764 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *